Aurora Cannabis (ACB) Acquiring Reliva is a Positive Step, Stifel Reiterates Sell
Tweet Send to a Friend
Stifel analyst Andrew Carter reiterated a Sell rating and 6.20CAD price target on Aurora Cannabis (NYSE: ACB) but noted that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
